Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand

Management of Advanced Non-Small Cell Lung Cancer and Clinical Outcomes in Patients Who Received Gefitinib (IRESSA) in Tertiary Care Setting in Thailand

The purpose of this study is to determine progression-free survival of lung cancer patients who received gefitinib in clinical practice in Thailand.

Inclusion Criteria:

• Diagnosed as having lung cancer based on histological/cytological findings
• Admitted to the hospital between January 2004 and December 2008
• Treated with gefitinib for at least 3 months

Exclusion Criteria:

• Involvement in the planning and/or conduct of the study
• Participation in another clinical study during the last 3 months